Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Polaryx Therapeutics, Inc.
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
May 28, 2026
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
May 26, 2026
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
May 23, 2026
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
May 22, 2026
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
May 22, 2026
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
May 20, 2026
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
May 17, 2026
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
May 16, 2026
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
February 3, 2026
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”
February 2, 2026
1
2
Next Page
→